Concepts (571)
Concepts are derived automatically from a person's publications.
The timeline below shows the dates (blue tick marks) of publications associated with LUIS E FAYAD's top concepts. The average publication date for each concept is shown as a red circle, illustrating changes in the primary topics that LUIS E FAYAD has written about over time.
Antibodies, MonoclonalAntineoplastic AgentsLymphoma, B-CellAntibodies, Monoclonal, Murine-DerivedLymphoma, Non-HodgkinMiddle AgedLymphoma, Mantle-CellHodgkin DiseaseDoxorubicinVincristineLymphomaAntineoplastic Combined Chemotherapy ProtocolsSalvage TherapyCyclophosphamideRituximabLymphoma, FollicularPrednisoneLymphoma, T-Cell, PeripheralLymphoma, Large B-Cell, DiffuseLymphoma, B-Cell, Marginal Zone
To see the data from this visualization as text,
click here.
Name | Number of Publications | First Publication Year | Most Recent Publication Year | Average Publication Date |
Antibodies, Monoclonal | 25 | 2005 | 2020 | November 2010 |
Antineoplastic Agents | 30 | 2004 | 2021 | October 2011 |
Lymphoma, B-Cell | 24 | 2003 | 2023 | November 2011 |
Antibodies, Monoclonal, Murine-Derived | 35 | 2005 | 2020 | March 2012 |
Lymphoma, Non-Hodgkin | 29 | 2003 | 2021 | May 2012 |
Middle Aged | 139 | 2003 | 2022 | August 2013 |
Lymphoma, Mantle-Cell | 29 | 2003 | 2023 | September 2013 |
Hodgkin Disease | 28 | 2003 | 2020 | October 2013 |
Doxorubicin | 40 | 2005 | 2023 | May 2014 |
Vincristine | 31 | 2005 | 2023 | May 2014 |
Lymphoma | 13 | 2006 | 2019 | July 2014 |
Antineoplastic Combined Chemotherapy Protocols | 101 | 2003 | 2023 | August 2014 |
Salvage Therapy | 16 | 2004 | 2021 | November 2014 |
Cyclophosphamide | 37 | 2005 | 2023 | November 2014 |
Rituximab | 62 | 2005 | 2023 | December 2014 |
Lymphoma, Follicular | 24 | 2003 | 2023 | January 2015 |
Prednisone | 19 | 2008 | 2023 | June 2015 |
Lymphoma, T-Cell, Peripheral | 7 | 2013 | 2019 | November 2016 |
Lymphoma, Large B-Cell, Diffuse | 54 | 2007 | 2023 | April 2017 |
Lymphoma, B-Cell, Marginal Zone | 9 | 2010 | 2023 | July 2018 |
To return to the timeline,
click here.